BOS 161721

Drug Profile

BOS 161721

Alternative Names: BOS161721

Latest Information Update: 09 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator MedImmune
  • Developer Boston Pharmaceuticals
  • Class Monoclonal antibodies
  • Mechanism of Action Interleukin 21 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Systemic lupus erythematosus
  • Phase I Autoimmune disorders

Most Recent Events

  • 27 Apr 2018 Boston Pharmaceuticals completes a phase I trial in Autoimmune disorders (In volunteers) in USA (IV) (SC) (NCT03036865)
  • 15 Dec 2017 Phase-I/II clinical trials in Systemic lupus erythematosus in USA (SC) (NCT03371251)
  • 09 Jan 2017 Phase-I clinical trials in Autoimmune disorders (In volunteers) in USA (IV) (NCT03036865)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top